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Abstract
We hypothesized that the magnitude of the association between plasma homocysteine concentration and cognitive performance is larger for
ApoE-4 carriers than for non-carriers. Nine hundred eleven dementia-free and stroke-free subjects (59% women) from the Maine-Syracuse study
(26–98 years old) were stratified into no-ApoE-4 (n = 667) and ApoE-4 carrier (n = 244) cohorts. Employing a cross-sectional design and multiple
regression analyses, plasma homocysteine was related to multiple domains of cognitive performance within these cohorts. When unadjusted, and
with adjustment for age, education, gender, ethnicity, and previous cognitive examinations, homocysteine concentrations were inversely related
to cognitive performance within both ApoE cohorts, with higher magnitude of associations within the ApoE-4 cohort. With adjustment for
cardiovascular disease risk factors, cardiovascular disease, and B-vitamin concentrations, the higher magnitude of associations between plasma
homocysteine and cognitive performance within the ApoE-4 cohort relative to the no-ApoE-4 cohort persisted; but associations of plasma
homocysteine and cognitive performance were attenuated and no longer significant within the no-ApoE-4 cohort. Presence of the ApoE-4 allele
modifies the relation between plasma homocysteine and cognitive performance.
© 2007 Elsevier Ireland Ltd. All rights reserved.
Keywords: ApoE; Homocysteine; Cardiovascular risk factors; Vitamins; Cognitive performance

Elevated plasma homocysteine (tHcy) is a risk factor for
cognitive deficit [2,7,11,12,28,33,37,38,45], cognitive decline
[26,46], and dementia [5,25,40]. It has been hypothesized that
tHcy is associated with lowered cognitive function via its positive association with other risk factors for cardiovascular disease
(CVD) and CVD-related events [11,12,35]. Other possibilities
are that vitamins involved in tHcy metabolism, folic acid, vitamin B6 and vitamin B12 , [39] confound relations between tHcy
and cognition [19] and/or tHcy itself has neurotoxic and excitotoxic properties [14,20,24,32].
ApoE is a lipoprotein involved in lipid transport and neuronal repair and synaptogenesis after injury [30]. The protein has
three isoforms, ApoE-2, ApoE-3, and ApoE-4. The ApoE-4
genotype represents a genetic risk factor for Alzheimer’s disease
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[13,36] and may also be a risk factor for lowered cognitive performance and cognitive decline in healthy individuals [1,43].
ApoE-4 carriers are also more vulnerable to cognitive deficits
related to risk factors such as low vitamin B12 blood concentrations [3,4], peripheral vascular disease and atherosclerosis [15].
Yet, despite the evidence that both higher levels of tHcy and
the presence of the ApoE-4 allele are related to poorer cognitive performance, few studies have tested the hypothesis that the
ApoE-4 genotype modifies relations between plasma tHcy and
cognitive performance [7,38].
In a community sample of persons 50–70 years old, the
association of higher tHcy with poorer performance on the
Rey Auditory Verbal Learning Test was stronger in persons
homozygous for the ApoE-4 allele as compared to all other
participants [38]. However, another community sample study of
persons 61–73 years old did not find that associations of tHcy
with cognitive decline were moderated by the ApoE-4 allele
[7].
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Given the inconsistencies in the few studies available, we
tested the following hypotheses with respect to non-demented
community-based adults: (1) compared to persons without the
ApoE-4 allele, the magnitude of the association between tHcy
and cognitive performance is greater for ApoE-4 allele carriers;
(2) this modification of relations between tHcy and cognition by
ApoE genotype is not limited to global cognitive performance
but is evident for specific cognitive domains; and (3) this modification will be observed with adjustment for CVD events, CVD
risk factors, and blood concentrations of B-vitamins (folate,
vitamin B6 , and vitamin B12 ).
The University of Maine approved this investigation.
Informed consent for data collection was obtained from all
participants in this community-based sample from the MaineSyracuse Longitudinal Study (MSLS), which began in 1975.
Recruitment and data collection procedures for the MSLS have
been described in detail [11]. This study is a cross-sectional
analysis of data obtained at the sixth wave of MSLS testing
(2001–2006), the first and only wave for which tHcy and ApoE
data were obtained. Of the 965 participants, aged between 26 and
98 years, subjects were excluded in the following sequence: (1)
no-ApoE genotype data obtained (n = 6); (2) dementia (n = 9);
(3) stroke (n = 32), (4) active dialysis treatment (n = 5); (5)
treatment for alcoholism (n = 1); (6) inability to read test material (n = 1). Stroke, defined as a focal neurological deficit of
acute onset persisting more than 24 h, was based on selfreport and record review (with permission), but confirmed by
hospitalization, treatment, or both. The clinical diagnosis of
dementia was determined from cognitive data, self-report, and
medical records, using the National Institute of Neurological
and Communicative Diseases and Stroke/Alzheimer’s Disease
and Related Disorders Association (NINCDS-ADRDA) criteria [27]. The characteristics of the final sample (n = 911) are
presented in Table 1.
Participants completed the Center for Epidemiological Studies Depression Scale (CES-D [34]) within one week prior to
neuropsychological testing. Following a fast from midnight,
a blood sample was drawn and a light breakfast was served.
A physical examination and neuropsychological testing followed.
Fasting blood samples were collected in standard ethylenediaminetetraacetic acid tubes for plasma tHcy and plasma B6
determinations and in serum separator (gel and clot activator)
tubes for serum determinations. Plasma tHcy concentrations
were assessed using a fluorescence polarization immunoassay,
which has a coefficient of variation for tHcy assays of less than
3.5% [41]. Determination of plasma vitamin B6 , high sensitivity
C-reactive protein (hs-CRP), serum folate, serum vitamin B12 ,
total cholesterol, triglycerides, glucose, and creatinine was performed as recently described [11]. Standard ApoE genotyping
used polymerase chain reaction (PCR) and restriction enzyme
digest with HhaI [11,17].
We employed the Mini Mental State Examination (MMSE)
and the Maine-Syracuse neuropsychological test battery [11],
which included the Similarities test from the Wechsler Adult
Intelligence Scale (WAIS) and four composite scores resulting
from a previous factor analysis which identified four relatively
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independent cognitive domains: Visual-Spatial Memory and
Organization, Scanning and Tracking, Verbal Episodic Memory
and Working Memory. Each composite score was constructed
by summing standard scores for multiple individual tests taken
from the Halstead Reitan Neuropsychological Test Battery, the
Wechsler Memory Scale-R, the original WAIS, and the WAIS III
[23].
Test scores were transformed to z-scores. This linear
transformation results in a mean of zero and a S.D. of 1.00
for each test and enables expression of regression coefficients
for the cognitive measures in terms of S.D. units. Factor
analytic methods and tests making up the composites are fully
described in a recent paper [11] and in the online supplement
(http://www.sciencedirect.com/science/journal/03043940).
These previously identified composites were confirmed via
replication of the factor analysis. Similarities (abstract reasoning) scores loaded on multiple factors and were treated as a
separate measure. In addition to composite scores based on
factor analysis, a Global Composite score was calculated by
averaging the z-scores for all individual tests (excluding the
MMSE). The Global Composite and MMSE were considered
separate measures of global performance.
A natural log transformation of the raw plasma tHcy values
(ln-tHcy) was necessary in order to achieve a normal distribution.
ApoE genotype was categorized as one or two 4 alleles (ApoE4 cohort) versus no 4 alleles (no-ApoE-4 cohort) given the
small number with two 4 alleles (n = 30).
Covariates were organized into three sets. The Basic set
included age (years), gender, education (years), number of
exposures to neuropsychological tests prior to wave six, and
race/ethnicity (non-Hispanic Caucasian or other). The CVD
set included CVD event/s (yes/no), diabetes mellitus (yes/no),
systolic blood pressure (mmHg, BP), presence of mild renal dysfunction (yes/no), total cholesterol (mg/dl), body mass index
(kg/m2 , BMI), depressed mood (yes/no), hs-CRP, and selfreported number of cigarettes smoked (per week), alcohol
consumption (cl/week), and coffee consumption (number of
24 cl cups/day). Diabetes mellitus was defined as follows: treatment with insulin, oral antidiabetic agents, or fasting glucose
level of 126 mg/dl or above. Mild renal dysfunction was defined
as an estimated creatinine clearance using the Cockcroft–Gault
formula [6] of less than 60 ml/min [22]. Using the Framingham
Study criteria [9], the CVD event variable was defined by the
presence of any of the following: myocardial infarction (3.9%),
coronary artery disease (7.7%), congestive heart failure (2.3%),
angina pectoris (5.3%), or transient ischemic attack (3.7%). The
B-vitamin set included blood concentrations of folate, vitamin
B6 and vitamin B12 . All of the covariates were related significantly to the independent variables, the dependent variables, or
both.
The relation between ln-tHcy and the measures of cognitive functioning was adjusted in a hierarchical progression
of regression models using the sets of covariates as follows:
(1) Unadjusted (no covariates); (2) the Basic set; (3) the
Basic + CVD set; and (4) the Expanded set (Basic + CVD + Bvitamins). All variables within each model were entered
simultaneously.
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Table 1
Demographic and health characteristics of the no-ApoE-4 allele and the ApoE-4 allele cohorts
Variable

Homocysteine (mol/l)
Age (years)
Education (years)
Folate (ng/dl)
Vitamin B6 (PLPa ), nmol/l
Vitamin B12 (pg/ml)
C-reactive protein
Systolic BP (mmHg)
Diastolic BP (mmHg)
Alcohol (cl/week)
Cigarettes (week)
Total cholesterol (mg/dl)
Body mass index (kg/m2 )
Coffee (cups/day)
Gender (female)
Ethnicity (caucasian)
Diabetes mellitus
Obesity (BMI ≥ 29.9 kg/m2 )
CVD event
Mild renal dysfunction
Depressed moodb
Folate deficitc
Vitamin B6 deficitd
Vitamin B12 deficite
Quintile 5 homocysteinef
a
b
c
d
e
f

No-ApoE-4 allele (n = 667)
Mean

S.D.

10.0
62.6
14.6
17.3
95.6
533.7
4.4
132.3
71.1
4.5
8.2
202.3
29.5
1.8

3.6
12.9
2.7
5.2
92.2
288.1
4.8
21.3
10.1
7.8
34.5
40.0
5.9
1.9

ApoE-4 allele (n = 244)
%

58.5
91.6
12.4
40.5
15.1
17.1
10.2
0.0
14.6
3.5
19.8

Mean

S.D.

9.8
60.7
14.6
16.8
87.9
511.0
3.3
129.6
69.9
4.8
12.8
201.6
29.4
1.8

3.2
12.3
2.8
5.2
86.5
258.6
3.6
22.2
9.7
10.1
43.2
39.3
6.4
1.9

%

60.7
87.3
13.9
41.0
14.8
16.0
10.7
0.0
14.8
4.1
20.1

Pyridoxal 5 -phosphate.
CES-depression scores >16.
Folate deficiency defined as value <3 ng/ml.
Vitamin B6 deficiency defined as value <30 nmol/l.
Vitamin B12 deficiency defined as value <200 pg/ml.
Homocysteine values ≥11.8 mol/l.

Residual plots and absence of significant quadratic trends
(ps > .20) confirmed the appropriateness of the straight-line fit
for tHcy. For each model, tests of interactions of the independent
variables with age and gender were statistically non-significant
(ps > .10).
The number of persons classified into the possible ApoE
genotypes was as follows: 2/2 (n = 17), 2/3 (n = 103), 2/4
(n = 21), 3/3 (n = 547), 3/4 (n = 193), and 4/4 (n = 30). The ApoE4 cohort (2/4, 3/4, 4/4) represented 26.6% of our sample. This
representation is within the range (24–30%) reported in other
studies of ApoE [3,15,38].
The ApoE-4 cohort was younger (t = 2.00, p < .05), had
lower hs-CRP values (t = 3.51, p < .001) than the no-ApoE-4
cohort and had a modestly higher proportion (χ2 = 3.84, p < .05)
of minority persons (Table 1). No differences between ApoE
cohorts were observed for mean tHcy or B-vitamin concentrations, low vitamin or high tHcy status, or other demographic or
health variables (p range = .09–.95).
With main effects in the model, statistically significant ApoE
by tHcy interactions (p < .05) were observed for the Unadjusted
model and for one or more adjusted models for the Global composite, the MMSE, Working Memory, and Similarities. Thus in
a second step with respect to evaluating effect modification of
tHcy by ApoE, t-tests of the differences between regression coef-

ficients obtained for the two ApoE-4 cohorts were performed
for these variables. Table 2 shows the regression coefficients for
each ApoE group for the Global composite, the MMSE, Working
Memory, and Similarities. It may be seen that regression coefficients were consistently higher for the ApoE-4 cohort than
for the no-ApoE-4 cohort. Significant differences (Table 2)
between regression coefficients were obtained for each of the
four variables. However, for the Global composite and Similarities, differences between the regression coefficients did not
achieve statistical significance with adjustment for the Basic and
the Basic + CVD covariate sets, respectively.
For the Unadjusted model, statistically significant inverse
associations between tHcy and each cognitive score were
obtained within the no-ApoE-4 and the ApoE-4 cohort. For
the Basic model, all regression coefficients remained statistically significant for the ApoE-4 cohort, but only the regression
coefficient for the Global composite remained significant for
the no-ApoE-4 cohort. When the CVD covariate set was introduced, and with further addition of the B-vitamin set, none
of the regression coefficients for the no-ApoE-4 cohort were
significant. For these models regression coefficients within the
ApoE-4 cohort remained significant for the Global composite,
MMSE, and Working Memory but were non-significant for Similarities. It should be noted that with adjustment for the Basic
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Table 2
Regression coefficients (β), standard errors (S.E.) and significance levels (p<) for t-tests of the differences between regression coefficients for the No-Apoe-4 and
Apoe-4 groups relating natural log plasma homocysteine to the cognitive measuresa
Cognitive outcome

Unadjusted model

Basic model

Basic + CVD model

Expanded model

No-Apoe4

Apoe-4

p<

No-Apoe4

Apoe-4

p<

No-Apoe4

Apoe-4

p<

No-Apoe4

Apoe-4

p<

Global
β
S.E.

−.807***
.123

−1.120***
.216

.05

−.213*
.106

−.412*
.177

NS

−.029
.110

−.491**
.186

.001

.054
.118

−.460*
.196

.001

MMSE
β
S.E.

−.471***
.124

−.805***
.235

.05

−.183
.127

−.602**
.219

.01

−.041
.129

−.658**
.234

.001

.060
.139

−.562*
.250

.001

Similarities
β
S.E.

−.379**
.126

−.852***
.223

.01

−.202
.121

−.493*
.206

.05

−.087
.128

−.377
.222

.045
.137

−.288
.234

.05

Working memory
β
S.E.

−.376**
.127

−.922***
.217

.001

−.103
.129

−.568*
.223

.01

.019
.137

.013
.148

−.663**
.248

.001

−.712**
.233

NS

.001

NS, non-significant.
a Values for t-tests of differences between βs are shown in the online supplement (Table S2, http://www.sciencedirect.com/science/journal/03043940).
* p < .05.
** p < .01.
*** p < .001.

covariate set, Similarities scores were significantly (p < .05) correlated with five of the eleven CVD covariates (BMI, CVD
events, diabetes, systolic BP, and alcohol use; r range = +.11 to
−.20), while the other cognitive variables were correlated with
no more than three CVD variables (r range = +.14 to −.23).
Statistically significant main effects for the Unadjusted and
Basic models were observed for the Visual Spatial Memory
and Organization (β = −0.785, p < .001; β = −0.277, p < .01)
and Scanning and Tracking (β = −1.011, p < .001; β = −0.300,
p < .01) composites. The Scanning and Tracking main effect persisted with adjustment for the CVD covariate set (β = −0.209,
p < .05), but was attenuated when B-vitamins were added to the
model (β = −0.174, p > .05). A main effect observed for the
Verbal Episodic Memory composite in the Unadjusted model
(β = −0.494, p < .001) did not persist with adjustment for the
Basic covariate set (β = 0.078, p > .20).
In a final analysis, two CVD sub-models were formed from
the CVD covariate set. The first sub-model included the following “primary” CVD variables: CVD events, diabetes mellitus,
systolic BP, mild renal dysfunction, total cholesterol, BMI, and
hs-CRP. The second, a “life style set”, included depressed mood
and cigarette, alcohol, and coffee consumption. Findings for
both sub-models were the same as those reported above for the
CVD model.
To illustrate the magnitude of statistical effects, we compared persons with tHcy values in the highest quintile (Q5,
tHcy > 11.8 mol/l) versus the lower four quintiles (Q1–Q4)
with regard to two overall measures of cognitive performance,
the MMSE and the Global composite, with adjustment for
the expanded covariate set. Within the ApoE-4 cohort, persons in tHcy Q5 performed close to 0.30S.D. units below
persons in the lower tHcy quintiles on the Global composite (β = −0.294, p < .04). This difference between persons in

tHcy Q5 and persons in Q1–Q4 was at 0.40S.D. for the MMSE
(β = −0.402, p < .01). However, within the no-ApoE-4 cohort,
persons in tHcy Q5 did not differ in performance from persons
in Q1–Q4 on either the Global composite (β = −0.016, p > .50)
or the MMSE (β = −0.008, p > .50). Differences between these
regression coefficients for the ApoE cohorts (β = −0.294 versus
−0.016 and β = −0.402 versus −0.008, respectively) were statistically significant for both the Global composite and MMSE
(ps < .01).
The magnitude of inverse association between tHcy and cognition was consistently higher for the ApoE-4 cohort than
for the no-ApoE-4 cohort for all covariate models. Results
within each ApoE cohort varied somewhat depending upon the
model employed. For instance, with no adjustment for covariates, significant inverse associations for all cognitive variables
were observed for both ApoE cohorts. With adjustment for the
basic covariate set, primarily demographic characteristics, only
the significant result for the Global composite remained for the
no-ApoE-4 cohort. However, results persisted for the ApoE4 cohort for the Global Composite, MMSE, Similarities, and
Working Memory.
With further adjustment for the CVD and the B-vitamin
covariate sets, the inverse relation between tHcy and Global cognitive performance for the no-ApoE-4 cohort was markedly
attenuated and non-significant. In contrast, for the ApoE-4
cohort, further adjustment for the CVD and the expanded covariate set resulted in only modest attenuation of inverse relations
between tHcy and cognitive performance for the Global composite, MMSE, and Working Memory. Associations between
Similarities (abstract reasoning) scores and tHcy did not persist
with adjustment for the CVD covariate set. The greater attenuation of the association between tHcy and Similarities scores, as
compared to Global composite, MMSE, and Working Memory
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scores, may reflect the fact that Similarities was correlated significantly with a greater number of the CVD variables than were
the other cognitive scores.
Although the interaction between ApoE genotype and tHcy
has been studied at the cellular level to explain their effect on
atheroma formation [21,47] and neuronal cell cycle dysregulation in the brain [29], only two studies report the modification of
tHcy relations with cognitive performance by the ApoE genotype. Dufouil et al. [7] did not find that ApoE genotype modified
associations of tHcy with cognitive decline. Schafer et al. [38]
found that the cross-sectional association of tHcy with performance on the Rey Auditory Verbal Learning Test was stronger
in individuals homozygous for the ApoE-4 allele than those
carrying only one 4 allele or no 4 alleles. Our study differed
from this study in that we employed fasting tHcy values, adjusted
for vitamin concentrations as well as CVD factors and combined
cohorts carrying either one or two ApoE-4 alleles for our major
analyses given statistical power considerations.
Because of the evidence that higher tHcy might be neurotoxic
[14,20,24,32], it is instructive to consider potential mechanisms
involved in the relation between the ApoE-4 allele and cognitive performance, particularly those mechanisms pertaining
to neuronal damage and repair. It has been argued that atrophy of the hippocampus and loss of its connectivity play a role
in ApoE-4-related deficits in test performance depending on
memory [43]. Also, there is evidence that cholinergic transmitter decrements in those persons with an ApoE-4 genotype are
seen in temporo-parietal brain areas involving integrative, psychomotor and visual abilities [31]. Small et al. [42] argue that
the interplay between several mechanisms may better explain
the broad range of deficits seen in ApoE-4 carriers. ApoE-4
is related to cardiovascular disease [16,42,44] which, in turn, is
related to cognitive deficit [10]. ApoE-4 genotype has also been
implicated in the altered metabolism of beta-amyloid and the
formation of neurofibrillary tangles [44]. Additionally, ApoE4 genotype is related to impairments in neuronal maintenance
and repair [18]. Though speculative, the interplay between tHcy
and ApoE-4 genotype may be more than a summation of different deleterious effects, i.e. ApoE-4 genotype is associated with
neuronal susceptibility to insult while higher tHcy is associated
with greater neuronal death.
Limitations of this study include: (1) the cross-sectional
design; and (2) the relatively high levels of education of our
participants which may serve to attenuate the magnitude of associations between tHcy and cognitive performance for both ApoE
cohorts.
In an era focused on pre-clinical disease and prevention,
the magnitude of the impact of plasma tHcy and ApoE genotype on cognitive performance is crucial. With adjustment for
the Expanded model (Basic + CVD + B-vitamin covariates), we
found that persons with high, as versus low, plasma tHcy in the
presence of an ApoE-4 allele performed 0.30S.D. and 0.40S.D.
lower on the Global composite and the MMSE, respectively.
Deficits of this magnitude are of considerable importance at the
population level and constitute a risk factor for dementia [8].
Our results are consistent with a model in which the ApoE4 allele is seen as conferring vulnerability to other risk factors

and pathophysiological phenomena related to lower cognitive
performance [4]. Additional studies are needed in order to understand the mechanism explaining the interplay between plasma
tHcy and ApoE genotype with regard to cognitive performance
in a non-demented sample.
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